Fidelity Investments
CTXR icon

Fidelity Investments’s Citius Pharmaceuticals CTXR Stock Holding History

Fidelity Investments’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-140
Closed -$2.05K – 5534
2024
Q2 		$2.05K Sell
140
-571
-80% -$10.2K ﹤0.01% 4721
2024
Q1 		$15.9K Sell
711
-30
-4% -$548 ﹤0.01% 4102
2023
Q4 		$14K Buy
741
+640
+634% +$12.1K ﹤0.01% 4119
2023
Q3 		$1.73K Sell
101
-240
-70% -$5.7K ﹤0.01% 4571
2023
Q2 		$10.2K Buy
341
+327
+2,336% +$10.8K ﹤0.01% 4133
2023
Q1 		$396 Sell
14
-42
-75% -$1.21K ﹤0.01% 4819
2022
Q4 		$1.1K Buy
56
+48
+600% +$1.31K ﹤0.01% 4633
2022
Q3 		$0 Sell
8
-55
-87% -$1.51K ﹤0.01% 4923
2022
Q2 		$1K Buy
63
+43
+215% +$1.18K ﹤0.01% 4687
2022
Q1 		$1K Buy
+20
New +$790 ﹤0.01% 4770
2021
Q4 		– Hold
0
– – – 4414
2021
Q3 		– Hold
0
– – – 4434
2021
Q2 		– Hold
0
– – – 4332

Other funds holding CTXR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CCC
Chelsea Counsel Company Los Angeles, California $225M AUM 45.99% 1-Year Est. Return

Fidelity Investments's CTXR Position: Q3 2024 in Review

Fidelity Investments sold out of Citius Pharmaceuticals (CTXR) in Q3 2024, closing a stake of 140 shares — an estimated $2.05K sold.

Fidelity Investments first reported a position in CTXR in Q1 2022 and held it in 10 quarters. The position peaked at $15.9K in Q1 2024. 57 funds tracked by Wall St. Rank hold CTXR as of Q3 2024.

  • Fidelity Investments reported no remaining Citius Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Fidelity Investments sold 140 Citius Pharmaceuticals shares in Q3 2024, an estimated $2.05K.
  • Fidelity Investments first reported a position in Citius Pharmaceuticals in Q1 2022 and held it in 10 quarters.
  • Fidelity Investments's Citius Pharmaceuticals position peaked at $15.9K in Q1 2024.
  • 57 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2024.

Based on Fidelity Investments's 13F filing for Q3 2024, filed 13 Nov 2024.